Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has issued US patent relating to Moberg Pharma's topical treatment MOB-015 for the treatment onychomycosis and this patent is expected to be in effect until 2032.
Subscribe to our email newsletter
In September 2014, the company reported positive results from a Phase II trial of MOB-015.
The new patent includes composition of matter claims directed to a new topical formulation of terbinafine, as well as claims directed to methods of treatment of onychomycosis using that new formulation.
This new formulation provides improved penetration of terbinafine into and through the nail.
The company has showed, ex vivo as well as in vivo, that MOB-015 delivers high microgram levels of terbinafine into the nail, as well as through the nail plate into the nail bed.
Moberg Pharma CEO Peter Wolpert said: "The approval of the U.S. patent for MOB-015 is a key milestone in our strategic goal to become the No. 1 player in products relating to nail fungus.
"We are moving forward in discussions with potential industrial as well as financial partners for the phase III program, with the aim of starting phase III in 2016."
Moberg Pharma markets Kerasal Nail, the leading product in the US over-the-counter (OTC) fungal nail category, through its OTC sales team and through distributors in about 30 countries.
MOB-015 is a proprietary topical formulation of terbinafine developed internally by the company and builds on its experience from the OTC market.